BIOLASE (BIOL) Stock Fell 22% In A Month, Is The Stock Still Worth Buying?
BIOLASE Inc (NASDAQ: BIOL) stock fell 22% in the past month. In fact, the stock has been running below $1 for the past four months, and it is now at $0.59 per share, so, is the stock still worth buying?
Amsden Lindsay - July 23, 2021
Will BIOLASE (BIOL) Stock Return To One Dollar Above Again?
BIOLASE (NASDAQ: BIOL) stock fell by 5% at close on Thursday, but still rose by 23% so far this year. The company reported on Thursday afternoon that it had an increase of 70% in revenue growth for the first quarter of 2021, which might drive its stock to return to $1 above again.
InvestReader Editor - May 13, 2021
Is BIOLASE (BIOL) Stock Worth Buying?
BIOLASE (NASDAQ: BIOL) stock was up by 43% so far this year. The company's business has also been affected by the pandemic over the past year. However, the company's net revenue began to grow significantly from the third quarter of last year, and its net revenue for the fourth quarter of 2020 was down by only 17% YoY.
InvestReader Editor - May 09, 2021
BIOL Stock: Is BIOLASE Stock Worth To Buy?
BIOLASE, Inc. (NASDAQ: BIOL) stock was up by 33.86% at close on Thursday. Despite the ongoing impact of the pandemic, the company still achieved strong revenue performance in the fourth quarter, this brings hope to its investors.
InvestReader Editor - April 08, 2021
ABCL Stock: AbCellera Biologics Up 46% After Reported FY 2020 Business Results
The reason investors are so excited is the earnings report embodies the company's strong growth in the past year.
InvestReader Editor - April 01, 2021